Fed Bio: designing gut microbiomes with staying power and enhancing immune-modulating bacteria

Fed Bio seeks to eliminate the need for repeated dosing of microbiome therapies for chronic diseases by designing complex bacterial communities that can stably colonize the gut.

The biotech, which emerged from stealth last week with a $50 million series A round, is complementing its consortia platform with engineered microbes that modulate T cells for cancer and autoimmune indications...